• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Simeprevir Responsible for Deaths in Japanese Hepatitis C Patients

Article

A spike in the blood bilirubin levels resulting in hepatic dysfunction and/or renal impairment was determined as the cause of death.

Sovriad (simeprevir sodium) was launched in Japan in December 2013. Of an estimated 18,900 patients taking the medication for hepatitis C infection, 3 deaths have been reported till October 2014. Hepatic and or renal impairement resulting from a significant increase in blood bilirubin levels was identified as the cause of death. The Pharmaceutical and Medical Devices Agency in Japan subsequently issued a "Dear Healthcare Professional Letter" and also asked Janssen to update the Warnings Subsection in the Precautions Section within the label.

Link to the letter issued by PMDA: http://bit.ly/1waEwBf

Related Videos
Dr Susan Vadaparampil
Luke Messac at ISC 2026
2 experts are featured in this series.
Ava Liberman at ISC 2026
Alison Holman at ISC 2026
Dr Ameet Patel
Linda Stein Gold, MD
Eric Levin, Scripta
Dr. Emily Fisher at ISC 2026
© 2026 MJH Life Sciences
AJMC®
All rights reserved.